Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYNCHRONY is a brand name for a combination herbicide product containing the active ingredients **chlorimuron-ethyl** and **thifensulfuron-methyl**. It is primarily used in agricultural settings, particularly for post-emergence weed control in soybean crops. The mechanism of action involves the inhibition of the enzyme acetolactate synthase (ALS), which is essential for the biosynthesis of branched-chain amino acids (leucine, isoleucine, and valine) in plants. By blocking this pathway, the herbicide causes a cessation of cell division and subsequent plant death in susceptible weed species. It is developed and marketed by DuPont (now part of Corteva Agriscience).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SYNCHRONY.